Other Events. Pursuant to that certain Registration Rights Agreement dated February 11, 2026 by and between Twist Bioscience Corporation (the “Company”) and Invenra Inc. (“Invenra”), the Company is filing a prospectus supplement to register the resale of shares issuable pursuant to that certain Stock Purchase Agreement dated February 11, 2026 by and between the Company and Invenra. An opinion of Orrick, Herrington & Sutcliffe LLP is filed as Exhibit 5.1 to this Current Report in connection wi…

Entry into a Material Definitive Agreement. On August 4, 2026, Twist Bioscience Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 3,125,000 shares of its common stock to the Underw…

Results of Operations and Financial Condition. On August 3, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Se…

Results of Operations and Financial Condition. On May 4, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Sect…

Other Events. Pursuant to Stock Purchase Agreements entered into with certain investors on February 11, 2026 (the “Stock Purchase Agreements”), Twist Bioscience Corporation (the “Company” or “Twist”) will issue up to an aggregate of 632,328 shares (the “Shares”) of its common stock, par value $0.00001 per share (the “Common Stock”). Of the Shares, the Company will issue up to 324,558 shares of Common Stock to Invenra Inc. (“Invenra”) and pay $5 million in cash in consideration for a license a…

Unregistered Sales of Equity Securities. The information set forth under

Results of Operations and Financial Condition. On February 2, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes…

Results of Operations and Financial Condition. On January 12, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its preliminary, unaudited revenue results for the first quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company’s revenue expectations included in this Current Report on Form 8-K are preliminary and unaudited and ar…

Results of Operations and Financial Condition. On November 14, 2025, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be…

Director — Trynka Shineman Blake: Appointment of Trynka Shineman Blake to the Board of Directors and Audit Committee.

Results of Operations and Financial Condition. On August 4, 2025, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Se…

Entry into a Material Definitive Agreement. On May 2, 2025, Twist Bioscience Corporation (“Twist”) entered into and closed on a Contribution Agreement (the “Contribution Agreement”) with Atlas Data Storage, Inc. (“Purchaser”), which secured approximately $155 million in investments, pursuant to which Purchaser acquired Twist’s DNA data storage product group, including certain intellectual property rights, equipment, contracts, and books and records related thereto (the “Contributed Assets”) a…

Regulation FD. In connection with the entry into the Contribution Agreement, License Agreement and MES Software License Agreement, Twist issued a press release, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information included in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deeme…

The excerpt is incomplete and does not provide sufficient details to determine the nature of the event.

Results of Operations and Financial Condition. On February 3, 2025, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes…

Results of Operations and Financial Condition. On November 18, 2024, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended September 30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be…

Strategic Advisor — James Thorburn: Mr. Thorburn transitioned into a month-to-month consulting agreement after the expiration of his employment agreement.

Results of Operations and Financial Condition. On August 2, 2024, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Se…

Results of Operations and Financial Condition. On May 2, 2024, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Sect…

Results of Operations and Financial Condition. On February 2, 2024, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes…

Chief Financial Officer — Adam Laponis: The company hired a new Chief Financial Officer from an external candidate.

Results of Operations and Financial Condition. On November 17, 2023, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended September 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be…

Costs Associated with Exit or Disposal Activities. As previously announced on May 5, 2023 and disclosed in the Original Report, on May 3, 2023, the Company’s board of directors approved a strategic restructuring plan, which included a reduction in force affecting approximately 270 employees worldwide, representing approximately 25% of the Company’s total workforce as of May 5, 2023. The reduction in force is subject to local regulatory requirements. Furthermore, as part of the plan, the Compa…

Chief Financial Officer — James Thorburn: Mr. Thorburn is transitioning to a new role while continuing as CFO until his successor starts.

Results of Operations and Financial Condition. On August 4, 2023, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Se…